Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer

被引:3
|
作者
Hotta, Takamasa [1 ,2 ]
Nariai, Yuko [1 ]
Kajitani, Naoyo [3 ]
Kadota, Kyuichi [4 ]
Maruyama, Riruke [4 ]
Tajima, Yoshitsugu [5 ]
Isobe, Takeshi [2 ]
Kamino, Hiroki [1 ,6 ,8 ]
Urano, Takeshi [1 ,6 ,7 ]
机构
[1] Shimane Univ, Fac Med, Dept Biochem, Izumo, Shimane 6938501, Japan
[2] Shimane Univ, Fac Med, Dept Internal Med, Div Med Oncol & Resp Med, Izumo, Shimane 6938501, Japan
[3] Shimane Univ, Org Res & Acad Informat, Dept Expt Anim, Interdisciplinary Ctr Sci Res, Izumo, Shimane 6938501, Japan
[4] Shimane Univ, Fac Med, Dept Pathol, Izumo, Shimane 6938501, Japan
[5] Shimane Univ, Fac Med, Dept Digest & Gen Surg, Izumo, Shimane 6938501, Japan
[6] mAbProtein Co Ltd, Izumo, Shimane 6938501, Japan
[7] Shimane Univ, Vaccines & Therapeut Antibodies Emerging Infect Di, Sch Med, Izumo 6938501, Japan
[8] Shimane Univ, Dept Biochem, Fac Med, 306 Basic Sci Bldg,89-1 Enya Cho, Izumo, Shimane 6938501, Japan
关键词
MIA PaCa-2; Monoclonal antibody; FXYD5; Epitope determination; Cancer prognosis; DYSADHERIN EXPRESSION; POOR-PROGNOSIS; E-CADHERIN; FXYD5; MOTILITY; PROMOTES; PROTEIN; NA;
D O I
10.1016/j.biochi.2023.01.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite recent advances in cancer treatments, pancreatic cancer has a dismal prognosis globally. Early detection of cancer cells and effective treatments for recalcitrant tumors are required, but the innovative therapeutic tools remain in development. Cancer-specific antigens expressed only on cancer cells may help resolve these problems, and antibodies to such antigens have potential in basic research and clinical applications. To generate specific antibodies that bind to proteins expressed on the surface of pancreatic cancer cells, we immunized mice with human pancreatic cancer MIA PaCa-2 cells, and isolated a hybridoma that produces a monoclonal antibody (mAb), named 12-13.8. This antibody was applied to molecular biological experiments such as immunocytochemistry, immunoblotting, flow cytometry, and immunoprecipitation. In addition, we showed that mAb 12-13.8 could accumulate in tumors, through in vivo experiments using cancer-bearing mice. Immunohistochemical staining of pancreatic and lung tumor tissues indicated that the increase of the staining strength by mAb 12-13.8 positively and inversely correlated with the patients' cancer recurrence and survival rate, respectively. We identified the FXYD5 protein as the target protein of mAb 12-13.8, by a human protein array screening system. The FXYD5 protein is overexpressed in various types of cancer and is modified by O-linked glycosylation. We confirmed the binding of the FXYD5 protein to mAb 12-13.8 by using FXYD5-knockout MIA PaCa-2 cells, and detailed epitope mapping identified amino acid residues 45-52 as the minimal peptide sequence. Our results indicate that mAb 12-13.8 could be a valuable tool for FXYD5 studies, and useful in diagnostic and drug delivery applications for cancer patients. & COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:160 / 169
页数:10
相关论文
共 50 条
  • [31] Novel application of anti-human Fc nanobody for screening high-producing CHO cells for monoclonal antibody
    Zhu, Di
    Wang, Zheng
    Xu, Yunxia
    Lin, Jing
    Qiu, Mei
    Liu, Jianghai
    Li, Xinlei
    ENGINEERING IN LIFE SCIENCES, 2022, 22 (10): : 608 - 618
  • [32] Human pancreatic cancer fusion 2 (HPC2) 1-B3: A novel monoclonal antibody to screen for pancreatic ductal dysplasia
    Morgan, Terry K.
    Hardiman, Karin
    Corless, Christopher L.
    White, Sandra L.
    Bonnah, Robert
    de Vrugt, Henry Van
    Sheppard, Brett C.
    Grompe, Markus
    Cosar, Ediz F.
    Streeter, Philip R.
    CANCER CYTOPATHOLOGY, 2013, 121 (01) : 37 - 46
  • [33] A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma
    Kaneko, Mika K.
    Ohishi, Tomokazu
    Kawada, Manabu
    Kato, Yukinari
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2020, 24
  • [34] Anti-metastatic effect of the TM4SF5-specific peptide vaccine and humanized monoclonal antibody on colon cancer in a mouse lung metastasis model
    Wu, Guang
    Kim, Dongbum
    Park, Byoung Kwon
    Park, Sangkyu
    Ha, Ji-Hee
    Kim, Te Ha
    Gautam, Avishekh
    Kim, Jung Nam
    Lee, Su In
    Park, Han-Bum
    Kim, Yong-Sung
    Kwon, Hyung-Joo
    Lee, Younghee
    ONCOTARGET, 2016, 7 (48) : 79156 - 79172
  • [35] Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: Identification of its antigen as a neutral glycolipid
    Kingsley, EA
    Carter, TE
    Barrow, KD
    Russell, PJ
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 41 (06) : 348 - 354
  • [36] Characterization of a Novel Anti-DR5 Monoclonal Antibody WD1 with the Potential to Induce Tumor Cell Apoptosis
    Jing Wang1
    2Institute of Basic Medical Sciences
    Cellular&MolecularImmunology, 2008, (01) : 55 - 60
  • [37] Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis
    Wang, Jing
    Lin, Zhou
    Qiao, Chunxia
    Lv, Ming
    Yu, Ming
    Xiao, He
    Wang, Qingyang
    Wang, Liyan
    Feng, Jiannan
    Shen, Beifen
    Ma, Yuanfang
    Li, Yan
    CELLULAR & MOLECULAR IMMUNOLOGY, 2008, 5 (01) : 55 - 60
  • [38] Characterization of a Novel Anti-DR5 Monoclonal Antibody WD1 with the Potential to Induce Tumor Cell Apoptosis
    Jing Wang
    Zhou Lin
    Chunxia Qiao
    Ming Lv
    Ming Yu
    He Xiao
    Qingyang Wang
    Liyan Wang
    Jiannan Feng
    Beifen Shen
    Yangfang Ma
    Yan Li
    Cellular & Molecular Immunology, 2008, 5 : 55 - 60
  • [39] A novel human monoclonal antibody derived from tumor-infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes
    Aoki, M
    Saikawa, Y
    Hosokawa, S
    Fukuda, K
    Kumai, K
    Kubota, T
    Yoshida, M
    Otani, Y
    Kitajima, M
    ANTICANCER RESEARCH, 2005, 25 (6B) : 3791 - 3798
  • [40] Development and characterization of TrMab-6, a novel anti-TROP2 monoclonal antibody for antigen detection in breast cancer
    Sayama, Yusuke
    Kaneko, Mika K.
    Kato, Yukinari
    MOLECULAR MEDICINE REPORTS, 2021, 23 (02)